|
|
Safety & Watchlist
Reliable picks + red flags
|
|
Safe Pick
|
|
ADP51 straight years of raises — this Dividend King processes your paycheck
|
Automatic Data Processing handles payroll for about 1 in 6 workers in the United States. Every two weeks, ADP calculates wages, withholds taxes, and deposits paychecks for millions of people. Once a company sets up payroll with ADP, switching is a headache nobody wants — that kind of stickiness is a moat.
ADP is a Dividend King — a company that has raised its dividend for 50 or more consecutive years. The current streak is 51 years. Through recessions, tech crashes, a pandemic — 51 straight years of higher payments. The payout ratio sits at about 59%, well within the safe zone. And the five-year dividend growth rate is around 12% annually.
The stock has pulled back roughly 22% from its highs, which has pushed the yield up to about 2.8%. That's the highest yield ADP has offered in years. For a name this reliable, that's worth paying attention to. Your $10,000 gets you $280 a year — and that $280 has grown every single year for half a century.
|
|
Yield: 2.8%
|
$10K invested = $280/yr
|
Paid: Quarterly
|
|
|
|
Red Flag
|
|
PFEPfizer's 7.15% yield is a warning sign, not a gift
|
Pfizer makes drugs — including the COVID vaccine that made it a household name during the pandemic. At 7.15%, the yield grabs your attention immediately. But I need to be straight with you about what's underneath.
The payout ratio is 131%. That means Pfizer is paying out more in dividends than it earns. And in 2025, Pfizer's cash flow fell about $700 million short of covering the dividend. When a company can't pay its dividend from what it actually generates in cash, that's a problem — regardless of what management says on earnings calls.
Here's why this is happening: Pfizer is facing a patent cliff. Its top-selling drug Eliquis (roughly $8 billion in annual sales) is losing patent protection, with European exclusivity already gone as of May 2026. Combined with declining COVID product revenue, analysts estimate Pfizer could lose $17 billion in annual revenue by 2030.
The stock is already down 60% from its 2022 high. Management says the dividend is a priority, and the estimated 2026 earnings-based payout ratio of 57% looks better on paper. But cash flow tells a different story. I'm not touching this one until the numbers change.
|
|
|
|
|
The Extra Yield
This week's calendars, screens & answers
|
|
Don't miss this ex-date: Abbott Labs (ABT) goes ex-dividend July 15 — $0.63 per share, 54 consecutive years of increases. You need to buy by July 14 to get this one.
|
|
I ran a screen this morning: Stocks with payout ratios under 30% and 10+ years of consecutive raises. Only 14 names survived. COST and MA were two of them. Others on the list: MSFT, V, AAPL. I'll dig into more of them next week.
|
|
Someone asked me: "If the yield is under 1%, why bother?" Because at 14% annual dividend growth, Mastercard's yield on your original purchase price will be over 2.5% in 10 years — and the stock price will likely be much higher too. You're planting an oak tree, not picking a flower.
|
|
|
|
The Dispatch
|
|
Today was about growth — where the dividend is headed, not where it sits right now. Costco raised 13.1% with a 26% payout ratio. Mastercard raised 14% with an 18% payout ratio. ADP has done it 51 years in a row. And Pfizer reminded us that a 7% yield with a 131% payout ratio isn't a reward — it's a red flag. Tomorrow is Friday, so I'll pull together the week's best picks and give you an expanded Extra Yield. See you then.
|
|
— Charlie
|
|
|
|